NASDAQ:CHMAChiasma Stock Price, Forecast & News

Chiasma's stock was trading at $3.92 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CHMA stock has increased by 22.2% and is now trading at $4.79.
View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chiasma in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Chiasma.

Chiasma is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020.
View our earnings forecast for Chiasma.

Chiasma will be holding an earnings conference call on Monday, August 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Chiasma Inc (NASDAQ:CHMA) announced its quarterly earnings results on Thursday, May, 7th. The biotechnology company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by $0.05.
View Chiasma's earnings history.

3 Wall Street analysts have issued 1 year price targets for Chiasma's stock. Their forecasts range from $11.00 to $19.00. On average, they expect Chiasma's stock price to reach $16.00 in the next year. This suggests a possible upside of 234.0% from the stock's current price.
View analysts' price targets for Chiasma.

Headlines about CHMA stock have trended very positive on Saturday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Chiasma earned a media sentiment score of 4.0 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days.
View the latest news about Chiasma.

Chiasma saw a drop in short interest during the month of July. As of July 31st, there was short interest totaling 1,830,000 shares, a drop of 15.7% from the July 15th total of 2,170,000 shares. Based on an average daily trading volume, of 752,200 shares, the days-to-cover ratio is presently 2.4 days. Approximately 4.6% of the company's shares are sold short.
View Chiasma's Current Options Chain.

Some companies that are related to Chiasma include Cara Therapeutics (CARA), ORIC Pharmaceuticals (ORIC), Omeros (OMER), Morphic (MORF), Vectura Group (VEGPF), Assembly Biosciences (ASMB), Nkarta (NKTX), Legend Biotech (AMTI), ImmunoGen (IMGN), Passage Bio (KROS), ZIOPHARM Oncology (ZIOP), Tricida (TCDA), Akouos (AKUS), Frequency Therapeutics (FREQ) and Eagle Pharmaceuticals (EGRX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chiasma investors own include Arbutus Biopharma (ABUS), Bausch Health Companies (BHC), GW Pharmaceuticals PLC- (GWPH), BioDelivery Sciences International (BDSI), Viking Therapeutics (VKTX), Alnylam Pharmaceuticals (ALNY), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Exelixis (EXEL) and Progenics Pharmaceuticals (PGNX).

(CHMA) raised $76 million in an initial public offering on Thursday, July 16th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. Barclays and Cowen and Company acted as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.

Chiasma trades on the NASDAQ under the ticker symbol "CHMA."

Chiasma's stock is owned by a number of retail and institutional investors. Top institutional investors include Bessemer Group Inc. (0.13%), WINTON GROUP Ltd (0.13%), Virtu Financial LLC (0.09%), Trexquant Investment LP (0.07%), SG Americas Securities LLC (0.05%) and State Board of Administration of Florida Retirement System (0.03%). Company insiders that own Chiasma stock include Mark J Fitzpatrick, Raj Kannan, Roni Mamluk, Scott Minick and William Ludlam.
View institutional ownership trends for Chiasma.

CHMA stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, and WINTON GROUP Ltd.
View insider buying and selling activity for Chiasma.

CHMA stock was purchased by a variety of institutional investors in the last quarter, including Bessemer Group Inc., Virtu Financial LLC, Trexquant Investment LP, State Board of Administration of Florida Retirement System, ProShare Advisors LLC, and SG Americas Securities LLC. Company insiders that have bought Chiasma stock in the last two years include Mark J Fitzpatrick, Raj Kannan, Scott Minick, and William Ludlam.
View insider buying and selling activity for Chiasma.

Shares of CHMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CHMA stock can currently be purchased for approximately $4.79.

Chiasma has a market capitalization of $202.43 million. The biotechnology company earns $-36,320,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis. Chiasma employs 49 workers across the globe.

The official website for Chiasma is www.chiasmapharma.com.

Chiasma's mailing address is 140 Kendrick Street Building C East, Needham MA, 02494. The biotechnology company can be reached via phone at 617-928-5300 or via email at [email protected]